Carlos E. Irarrazabal

Previously to be an independent investigator Dr. Irarrázabal participate in several investigations in the Universidad de Chile. One of his most interesting research was to clarify the mechanisms involved in the specificity of the amino acid transporter y+L system in the human erythrocyte. Besides, he participates in an initiative from the Organization of American States to disseminate the biotechnology interaction between academics and industry. He was co-editor of two books in this area. During his doctoral thesis, he was awarded with two government support grants. The doctoral thesis help to identifies a p53 gene polymorphisms in humans associated with lung cancer susceptibility. After finished the Ph.D. program in the Universidad de Chile, he moved to Bethesda City in the U.S.A. to carry out his postdoc training in renal physiology in the National Institutes of Health (NIH-USA) under the supervision of Dr. Maurice Burg. In NIH, his contribution provided important evidence to understand how the cells survived in hypertonic condition in kidney, helping to clarify the knowledge of the renal function and the osmotic stress response signaling pathway. Right now, he is a full professor and Chief of the Laboratory of Integrative and Molecular Physiology in the Universidad de los Andes (UANDES) in Chile. He has over 30 publications that have been cited over 500 times, and his publication H-index is 18 and has been serving as an editorial board member of reputed Journals. In the UANDES, he has worked in more than 10 research projects generating two patents for clinical application in hypoxia and renal damage.